Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy

Abstract

Autism spectrum disorder (ASD) has become a common neurodevelopmental disorder. The heterogeneity of ASD poses great challenges for its research and clinical translation. On the basis of reviewing the heterogeneity of ASD, this review systematically summarized the current status and progress of pathogenesis, diagnostic markers, and interventions for ASD. We provided an overview of the ASD molecular mechanisms identified by multi-omics studies and convergent mechanism in different genetic backgrounds. The comorbidities, mechanisms associated with important physiological and metabolic abnormalities (i.e., inflammation, immunity, oxidative stress, and mitochondrial dysfunction), and gut microbial disorder in ASD were reviewed. The non-targeted omics and targeting studies of diagnostic markers for ASD were also reviewed. Moreover, we summarized the progress and methods of behavioral and educational interventions, intervention methods related to technological devices, and research on medical interventions and potential drug targets. This review highlighted the application of high-throughput omics methods in ASD research and emphasized the importance of seeking homogeneity from heterogeneity and exploring the convergence of disease mechanisms, biomarkers, and intervention approaches, and proposes that taking into account individuality and commonality may be the key to achieve accurate diagnosis and treatment of ASD.

Keywords

autism spectrum disorder / biomarker / intervention therapy / molecular mechanisms / multi-omics

References

1	L Kanner. Autistic disturbances of affective contact. Acta Paedopsychiatr. 1968;35(4):100-136.
2	H Asperger. Die “Autistischen psychopathen” im kindesalter. Arch Psychiat Nervenkrankheiten. 1944;117(1):76-136.
3	L Wing, J Gould. Systematic recording of behaviors and skills of retarded and psychotic children. J Autism Child Schizophr. 1978;8(1):79-97.
4	APA. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
5	E Fombonne. Editorial: the rising prevalence of autism. J Child Psychol Psychiatry. 2018;59(7):717-720.
6	K Lyall, L Croen, J Daniels, et al. The changing epidemiology of autism spectrum disorders. Annu Rev Public Health. 2017;38:81-102.
7	J Zeidan, E Fombonne, J Scorah, et al. Global prevalence of autism: a systematic review update. Autism Res. 2022;15(5):778-790.
8	MJ Maenner, KA Shaw, AV Bakian, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 Sites, United States, 2018. MMWR Surveill Summ. 2021;70(11):1-16.
9	MJ Maenner, Z Warren, AR Williams, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 Sites, United States, 2020. MMWR Surveill Summ. 2023;72(2):1-14.
10	H Zhou, X Xu, W Yan, et al. Prevalence of autism spectrum disorder in China: a nationwide multi-center population-based study among children aged 6 to 12 years. Neurosci Bull. 2020;36(9):961-971.
11	ZC Zhang, J Han. The first national prevalence of autism spectrum disorder in China. Neurosci Bull. 2020;36(9):959-960.
12	B Tick, P Bolton, F Happé, M Rutter, F Rijsdijk. Heritability of autism spectrum disorders: a meta-analysis of twin studies. J Child Psychol Psychiatry. 2016;57(5):585-595.
13	JN Constantino, Y Zhang, T Frazier, AM Abbacchi, P Law. Sibling recurrence and the genetic epidemiology of autism. Am J Psychiatry. 2010;167(11):1349-1356.
14	N Palmer, A Beam, D Agniel, et al. Association of sex with recurrence of autism spectrum disorder among siblings. JAMA Pediatr. 2017;171(11):1107-1112.
15	JH Miles, TN Takahashi, S Bagby, et al. Essential versus complex autism: definition of fundamental prognostic subtypes. Am J Med Genet A. 2005;135(2):171-180.
16	D Cohen, N Pichard, S Tordjman, et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord. 2005;35(1):103-116.
17	M Fakhoury. Autistic spectrum disorders: a review of clinical features, theories and diagnosis. Int J Dev Neurosci. 2015;43:70-77.
18	L Shen, X Liu, H Zhang, J Lin, C Feng, J Iqbal. Biomarkers in autism spectrum disorders: current progress. Clin Chim Acta. 2020;502:41-54.
19	H Won, W Mah, E Kim. Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses. Front Mol Neurosci. 2013;6:19.
20	I Voineagu, X Wang, P Johnston, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474(7351):380-384.
21	NN Parikshak, V Swarup, TG Belgard, et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature. 2016;540(7633):423-427.
22	D Velmeshev, M Magistri, EMC Mazza, et al. Cell-type-specific analysis of molecular pathology in autism identifies common genes and pathways affected across neocortical regions. Mol Neurobiol. 2020;57(5):2279-2289.
23	D Velmeshev, L Schirmer, D Jung, et al. Single-cell genomics identifies cell type-specific molecular changes in autism. Science. 2019;364(6441):685-689.
24	B Paulsen, S Velasco, AJ Kedaigle, et al. Autism genes converge on asynchronous development of shared neuron classes. Nature. 2022;602(7896):268-273.
25	A Masi, MM DeMayo, N Glozier, AJ Guastella. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull. 2017;33(2):183-193.
26	SS Jeste, DH Geschwind. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol. 2014;10(2):74-81.
27	TE Rosen, CA Mazefsky, RA Vasa, MD Lerner. Co-occurring psychiatric conditions in autism spectrum disorder. Int Rev Psychiatry. 2018;30(1):40-61.
28	T Hirota, BH King. Autism spectrum disorder: a review. JAMA. 2023;329(2):157-168.
29	P Howlin, S Goode, J Hutton, M Rutter. Savant skills in autism: psychometric approaches and parental reports. Philos Trans R Soc Lond B Biol Sci. 2009;364(1522):1359-1367.
30	DH Geschwind. Advances in autism. Annu Rev Med. 2009;60:367-380.
31	DM Werling, DH Geschwind. Sex differences in autism spectrum disorders. Curr Opin Neurol. 2013;26(2):146-153.
32	J Carayol, GD Schellenberg, B Dombroski, E Genin, F Rousseau, G Dawson. Autism risk assessment in siblings of affected children using sex-specific genetic scores. Mol Autism. 2011;2(1):17.
33	H Steeb, JM Ramsey, PC Guest, et al. Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome. Mol Autism. 2014;5(1):4.
34	D Sato, AC Lionel, CS Leblond, et al. SHANK1 deletions in males with autism spectrum disorder. Am J Hum Genet. 2012;90(5):879-887.
35	M Tropeano, JW Ahn, RJ Dobson, et al. Male-biased autosomal effect of 16p13.11 copy number variation in neurodevelopmental disorders. PLoS One. 2013;8(4):e61365.
36	M Tropeano, D Howley, MJ Gazzellone, et al. Microduplications at the pseudoautosomal SHOX locus in autism spectrum disorders and related neurodevelopmental conditions. J Med Genet. 2016;53(8):536-547.
37	I Mitra, K Tsang, C Ladd-Acosta, et al. Pleiotropic mechanisms indicated for sex differences in autism. PLoS Genet. 2016;12(11):e1006425.
38	L Wing. Sex ratios in early childhood autism and related conditions. Psychiatry Res. 1981;5(2):129-137.
39	NL Kreiser, SW White. ASD in females: are we overstating the gender difference in diagnosis? Clin Child Fam Psychol Rev. 2014;17(1):67-84.
40	L Tsai, MA Stewart, G August. Implication of sex differences in the familial transmission of infantile autism. J Autism Dev Disord. 1981;11(2):165-173.
41	RP Goin-Kochel, A Abbacchi, JN Constantino. Lack of evidence for increased genetic loading for autism among families of affected females: a replication from family history data in two large samples. Autism. 2007;11(3):279-286.
42	DS Messinger, GS Young, SJ Webb, et al. Early sex differences are not autism-specific: a Baby Siblings Research Consortium (BSRC) study. Mol Autism. 2015;6:32.
43	MJ Gazzellone, X Zhou, AC Lionel, et al. Copy number variation in Han Chinese individuals with autism spectrum disorder. J Neurodev Disord. 2014;6(1):34.
44	RO Rosti, AA Sadek, KK Vaux, JG Gleeson. The genetic landscape of autism spectrum disorders. Dev Med Child Neurol. 2014;56(1):12-18.
45	MV Lombardo, JL Barnes, SJ Wheelwright, S Baron-Cohen. Self-referential cognition and empathy in autism. PLoS One. 2007;2(9):e883.
46	L Damaj, A Lupien-Meilleur, A Lortie, et al. CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms. Eur J Hum Genet. 2015;23(11):1505-1512.
47	JM Fernandes, R Caj?o, R Lopes, R Jerónimo, JB Barahona-Corrêa. Social cognition in schizophrenia and autism spectrum disorders: a systematic review and meta-analysis of direct comparisons. Front Psychiatry. 2018;9:504.
48	G Chen, B Yu, S Tan, et al. GIGYF1 disruption associates with autism and impaired IGF-1R signaling. J Clin Invest. 2022;132(19):e159806.
49	S Goh, BS Peterson. Imaging evidence for disturbances in multiple learning and memory systems in persons with autism spectrum disorders. Dev Med Child Neurol. 2012;54(3):208-213.
50	S Connolly, R Anney, L Gallagher, EA Heron. Evidence of assortative mating in autism spectrum disorder. Biol Psychiatry. 2019;86(4):286-293.
51	P Ballester, AL Richdale, EK Baker, AM Peiró. Sleep in autism: a biomolecular approach to aetiology and treatment. Sleep Med Rev. 2020;54:101357.
52	F Abdul, N Sreenivas, JVS Kommu, et al. Disruption of circadian rhythm and risk of autism spectrum disorder: role of immune-inflammatory, oxidative stress, metabolic and neurotransmitter pathways. Rev Neurosci. 2022;33(1):93-109.
53	AS Yenen, HT ?ak. Melatonin and circadian rhythm in autism spectrum disorders. Turk Psikiyatri Derg. 2020;31(3):201-211.
54	H Ganesan, V Balasubramanian, M Iyer, et al. mTOR signalling pathway—a root cause for idiopathic autism? BMB Rep. 2019;52(7):424-433.
55	J Zhang, JX Zhang, QL Zhang. PI3K/AKT/mTOR-mediated autophagy in the development of autism spectrum disorder. Brain Res Bull. 2016;125:152-158.
56	KS Yeung, WWY Tso, JJK Ip, et al. Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism. Mol Autism. 2017;8:66.
57	M Costa-Mattioli, LM Monteggia. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci. 2013;16(11):1537-1543.
58	F Niere, S Namjoshi, E Song, et al. Analysis of proteins that rapidly change upon mechanistic/mammalian target of rapamycin complex 1 (mTORC1) repression identifies Parkinson protein 7 (PARK7) as a novel protein aberrantly expressed in tuberous sclerosis complex (TSC). Mol Cell Proteomics. 2016;15(2):426-444.
59	MV Lombardo, HM Moon, J Su, TD Palmer, E Courchesne, T Pramparo. Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder. Mol Psychiatry. 2018;23(4):1001-1013.
60	S Mencer, M Kartawy, F Lendenfeld, et al. Proteomics of autism and Alzheimer's mouse models reveal common alterations in mTOR signaling pathway. Transl Psychiatry. 2021;11(1):480.
61	H Wesseling, Y Elgersma, S Bahn. A brain proteomic investigation of rapamycin effects in the Tsc1(+/–) mouse model. Mol Autism. 2017;8:41.
62	VH Gazestani, T Pramparo, S Nalabolu, et al. A perturbed gene network containing PI3K-AKT, RAS-ERK and WNT-β-catenin pathways in leukocytes is linked to ASD genetics and symptom severity. Nat Neurosci. 2019;22(10):1624-1634.
63	H Wan, Q Wang, X Chen, et al. WDR45 contributes to neurodegeneration through regulation of ER homeostasis and neuronal death. Autophagy. 2020;16(3):531-547.
64	G Tang, K Gudsnuk, SH Kuo, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 2014;83(5):1131-1143.
65	J Pucilowska, J Vithayathil, M Pagani, et al. Pharmacological inhibition of ERK signaling rescues pathophysiology and behavioral phenotype associated with 16p11.2 chromosomal deletion in mice. J Neurosci. 2018;38(30):6640-6652.
66	EE Eichler, AW Zimmerman. A hot spot of genetic instability in autism. N Engl J Med. 2008;358(7):737-739.
67	K Murari, A Abushaibah, JM Rho, RW Turner, N Cheng. A clinically relevant selective ERK-pathway inhibitor reverses core deficits in a mouse model of autism. EBioMedicine. 2023;91:104565.
68	Q Li, Y Shi, X Li, et al. Proteomic-based approach reveals the involvement of apolipoprotein A-I in related phenotypes of autism spectrum disorder in the BTBR mouse model. Int J Mol Sci. 2022;23(23):15290.
69	SR Gilman, I Iossifov, D Levy, M Ronemus, M Wigler, D Vitkup. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron. 2011;70(5):898-907.
70	K Matic, T Eninger, B Bardoni, L Davidovic, B Macek. Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides new insights into FMRP-dependent signal transduction mechanisms. J Proteome Res. 2014;13(10):4388-4397.
71	C D'Incal, J Broos, T Torfs, RF Kooy, W Vanden Berghe. Towards kinase inhibitor therapies for fragile X syndrome: tweaking twists in the autism spectrum kinase signaling network. Cells. 2022;11(8):1325.
72	H Wesseling, PC Guest, CM Lee, EH Wong, H Rahmoune, S Bahn. Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. Mol Autism. 2014;5:38.
73	J Yang, X He, L Qian, et al. Association between plasma proteome and childhood neurodevelopmental disorders: a two-sample Mendelian randomization analysis. EBioMedicine. 2022;78:103948.
74	JM Berg, C Lee, L Chen, et al. JAKMIP1, a novel regulator of neuronal translation, modulates synaptic function and autistic-like behaviors in mouse. Neuron. 2015;88(6):1173-1191.
75	Y Nishimura, CL Martin, A Vazquez-Lopez, et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet. 2007;16(14):1682-1698.
76	A Pourtavakoli, S Ghafouri-Fard. Calcium signaling in neurodevelopment and pathophysiology of autism spectrum disorders. Mol Biol Rep. 2022;49(11):10811-10823.
77	BI Hutchins, L Li, K Kalil. Wnt-induced calcium signaling mediates axon growth and guidance in the developing corpus callosum. Sci Signal. 2012;5(206):pt1.
78	J Reilly, L Gallagher, G Leader, S Shen. Coupling of autism genes to tissue-wide expression and dysfunction of synapse, calcium signalling and transcriptional regulation. PLoS One. 2020;15(12):e0242773.
79	Y Wen, MJ Alshikho, MR Herbert. Pathway network analyses for autism reveal multisystem involvement, major overlaps with other diseases and convergence upon MAPK and calcium signaling. PLoS One. 2016;11(4):e0153329.
80	L Daroles, S Gribaudo, M Doulazmi, et al. Fragile X mental retardation protein and dendritic local translation of the alpha subunit of the calcium/calmodulin-dependent kinase II messenger RNA are required for the structural plasticity underlying olfactory learning. Biol Psychiatry. 2016;80(2):149-159.
81	AJ Baucum, BC Shonesy, KL Rose, RJ Colbran. Quantitative proteomics analysis of CaMKII phosphorylation and the CaMKII interactome in the mouse forebrain. ACS Chem Neurosci. 2015;6(4):615-631.
82	I Bezprozvanny, PR Hiesinger. The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol Neurodegener. 2013;8:23.
83	EM Guimar?es-Souza, C Joselevitch, LRG Britto, S Chiavegatto. Retinal alterations in a pre-clinical model of an autism spectrum disorder. Mol Autism. 2019;10:19.
84	M Rubinstein, RE Westenbroek, FH Yu, CJ Jones, T Scheuer, WA Catterall. Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome. Neurobiol Dis. 2015;73:106-117.
85	JL Rubenstein, MM Merzenich. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255-267.
86	SB Nelson, V Valakh. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron. 2015;87(4):684-698.
87	S Han, C Tai, RE Westenbroek, et al. Autistic-like behaviour in Scn1a+/– mice and rescue by enhanced GABA-mediated neurotransmission. Nature. 2012;489(7416):385-390.
88	MJ Gandal, JR Haney, B Wamsley, et al. Broad transcriptomic dysregulation occurs across the cerebral cortex in ASD. Nature. 2022;611(7936):532-539.
89	AE Purcell, OH Jeon, AW Zimmerman, ME Blue, J Pevsner. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001;57(9):1618-1628.
90	JR Abraham, N Szoko, J Barnard, et al. Proteomic investigations of autism brain identify known and novel pathogenetic processes. Sci Rep. 2019;9(1):13118.
91	M Pagani, N Barsotti, A Bertero, et al. mTOR-related synaptic pathology causes autism spectrum disorder-associated functional hyperconnectivity. Nat Commun. 2021;12(1):6084.
92	A Hoffmann, D Spengler. Single-cell transcriptomics supports a role of CHD8 in autism. Int J Mol Sci. 2021;22(6):3261.
93	M Lussu, A Noto, A Masili, et al. The urinary (1) H-NMR metabolomics profile of an Italian autistic children population and their unaffected siblings. Autism Res. 2017;10(6):1058-1066.
94	T Bitar, S Mavel, P Emond, et al. Identification of metabolic pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. J Pharm Biomed Anal. 2018;152:57-65.
95	F Gevi, A Belardo, L Zolla. A metabolomics approach to investigate urine levels of neurotransmitters and related metabolites in autistic children. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165859.
96	A Gagliano, F Murgia, AM Capodiferro, et al. (1)H-NMR-based metabolomics in autism spectrum disorder and pediatric acute-onset neuropsychiatric syndrome. J Clin Med. 2022;11(21):6493.
97	WJ Droogers, HD MacGillavry. Plasticity of postsynaptic nanostructure. Mol Cell Neurosci. 2023;124:103819.
98	S Jung, M Park. Shank postsynaptic scaffolding proteins in autism spectrum disorder: mouse models and their dysfunctions in behaviors, synapses, and molecules. Pharmacol Res. 2022;182:106340.
99	A Wise, E Schatoff, J Flores, et al. Drosophila-Cdh1 (Rap/Fzr) a regulatory subunit of APC/C is required for synaptic morphology, synaptic transmission and locomotion. Int J Dev Neurosci. 2013;31(7):624-633.
100	A Schmid, G Qin, C Wichmann, et al. Non-NMDA-type glutamate receptors are essential for maturation but not for initial assembly of synapses at Drosophila neuromuscular junctions. J Neurosci. 2006;26(44):11267-11277.
101	C Oliva, P Escobedo, C Astorga, C Molina, J Sierralta. Role of the MAGUK protein family in synapse formation and function. Dev Neurobiol. 2012;72(1):57-72.
102	EC Davenport, BR Szulc, J Drew, et al. Autism and schizophrenia-associated CYFIP1 regulates the balance of synaptic excitation and inhibition. Cell Rep. 2019;26(8):2037-2051.
103	I Iossifov, BJ O'Roak, SJ Sanders, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216-221.
104	J Li, W Zhang, H Yang, et al. Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders. Nat Neurosci. 2017;20(8):1150-1161.
105	C Jin, Y Lee, H Kang, et al. Increased ribosomal protein levels and protein synthesis in the striatal synaptosome of Shank3-overexpressing transgenic mice. Mol Brain. 2021;14(1):39.
106	D Reim, U Distler, S Halbedl, et al. Proteomic analysis of post-synaptic density fractions from Shank3 mutant mice reveals brain region specific changes relevant to autism spectrum disorder. Front Mol Neurosci. 2017;10:26.
107	S Lee, HS Chun, J Lee, et al. Plausibility of the zebrafish embryos/larvae as an alternative animal model for autism: a comparison study of transcriptome changes. PLoS One. 2018;13(9):e0203543.
108	YE Yoo, T Yoo, H Kang, E Kim. Brain region and gene dosage-differential transcriptomic changes in Shank2-mutant mice. Front Mol Neurosci. 2022;15:977305.
109	P Gupta, OE Uner, S Nayak, GR Grant, RG Kalb. SAP97 regulates behavior and expression of schizophrenia risk enriched gene sets in mouse hippocampus. PLoS One. 2018;13(7):e0200477.
110	J Jaworski, LC Kapitein, SM Gouveia, et al. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron. 2009;61(1):85-100.
111	A Alfieri, O Sorokina, A Adrait, et al. Synaptic interactome mining reveals p140Cap as a new hub for PSD proteins involved in psychiatric and neurological disorders. Front Mol Neurosci. 2017;10:212.
112	D Repetto, P Camera, R Melani, et al. p140Cap regulates memory and synaptic plasticity through Src-mediated and citron-N-mediated actin reorganization. J Neurosci. 2014;34(4):1542-1553.
113	S Thacker, C Eng. Transcriptome-(phospho)proteome characterization of brain of a germline model of cytoplasmic-predominant Pten expression with autism-like phenotypes. NPJ Genom Med. 2021;6(1):42.
114	M Quesnel-Vallières, Z Dargaei, M Irimia, et al. Misregulation of an activity-dependent splicing network as a common mechanism underlying autism spectrum disorders. Mol Cell. 2016;64(6):1023-1034.
115	C Walter, A Marada, T Suhm, et al. Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery. Nat Commun. 2021;12(1):4284.
116	JA Broek, PC Guest, H Rahmoune, S Bahn. Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins. Mol Autism. 2014;5:41.
117	JR Abraham, J Barnard, H Wang, et al. Proteomic investigations of human HERC2 mutants: insights into the pathobiology of a neurodevelopmental disorder. Biochem Biophys Res Commun. 2019;512(2):421-427.
118	P Zhang, A Omanska, BP Ander, MJ Gandal, B Stamova, CM Schumann. Neuron-specific transcriptomic signatures indicate neuroinflammation and altered neuronal activity in ASD temporal cortex. Proc Natl Acad Sci U S A. 2023;120(10):e2206758120.
119	L Boccuto, CF Chen, AR Pittman, et al. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013;4(1):16.
120	AM Smith, MR Natowicz, D Braas, et al. A metabolomics approach to screening for autism risk in the children's autism metabolome project. Autism Res. 2020;13(8):1270-1285.
121	D Brister, BA Werner, G Gideon, et al. Central nervous system metabolism in autism, epilepsy and developmental delays: a cerebrospinal fluid analysis. Metabolites. 2022;12(5):371.
122	SL Nolin, E Napoli, A Flores, RJ Hagerman, C Giulivi. Deficits in prenatal serine biosynthesis underlie the mitochondrial dysfunction associated with the autism-linked FMR1 gene. Int J Mol Sci. 2021;22(11):5886.
123	M Kartawy, I Khaliulin, H Amal. Systems biology reveals S-nitrosylation-dependent regulation of mitochondrial functions in mice with Shank3 mutation associated with autism spectrum disorder. Brain Sci. 2021;11(6):677.
124	G Golubiani, V Lagani, R Solomonia, M Müller. Metabolomic fingerprint of Mecp2-deficient mouse cortex: evidence for a pronounced multi-facetted metabolic component in Rett syndrome. Cells. 2021;10(9):2494.
125	HY Kim, YJ Lee, SJ Kim, et al. Metabolomics profiling of valproic acid-induced symptoms resembling autism spectrum disorders using 1H NMR spectral analysis in rat model. J Toxicol Environ Health A. 2022;85(1):1-13.
126	U Meyer. Neurodevelopmental resilience and susceptibility to maternal immune activation. Trends Neurosci. 2019;42(11):793-806.
127	ML Estes, AK McAllister. Maternal immune activation: implications for neuropsychiatric disorders. Science. 2016;353(6301):772-777.
128	N Usui, H Kobayashi, S Shimada. Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder. Int J Mol Sci. 2023;24(6):5487.
129	Y Zhu, CE Mordaunt, BP Durbin-Johnson, et al. Expression changes in epigenetic gene pathways associated with one-carbon nutritional metabolites in maternal blood from pregnancies resulting in autism and non-typical neurodevelopment. Autism Res. 2021;14(1):11-28.
130	Y Murakami, Y Imamura, Y Kasahara, et al. Maternal inflammation with elevated kynurenine metabolites is related to the risk of abnormal brain development and behavioral changes in autism spectrum disorder. Cells. 2023;12(7):1087.
131	T Nevalainen, L Kananen, S Marttila, et al. Increased paternal age at conception is associated with transcriptomic changes involved in mitochondrial function in elderly individuals. PLoS One. 2016;11(11):e0167028.
132	JE Buizer-Voskamp, W Laan, WG Staal, et al. Paternal age and psychiatric disorders: findings from a Dutch population registry. Schizophr Res. 2011;129(2-3):128-132.
133	L Wang, R Zheng, Y Xu, et al. Altered metabolic characteristics in plasma of young boys with autism spectrum disorder. J Autism Dev Disord. 2022;52(11):4897-4907.
134	C Cao, D Wang, M Zou, C Sun, L Wu. Untargeted metabolomics reveals hepatic metabolic disorder in the BTBR mouse model of autism and the significant role of liver in autism. Cell Biochem Funct. 2023;41(5):553-563.
135	J O'Neill, R Bansal, S Goh, M Rodie, S Sawardekar, BS Peterson. Parsing the heterogeneity of brain metabolic disturbances in autism spectrum disorder. Biol Psychiatry. 2020;87(2):174-184.
136	K Marballi, JL MacDonald. Proteomic and transcriptional changes associated with MeCP2 dysfunction reveal nodes for therapeutic intervention in Rett syndrome. Neurochem Int. 2021;148:105076.
137	F Ayhan, G Konopka. Regulatory genes and pathways disrupted in autism spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:57-64.
138	L Wang, B Wang, C Wu, J Wang, M Sun. Autism spectrum disorder: neurodevelopmental risk factors, biological mechanism, and precision therapy. Int J Mol Sci. 2023;24(3):1819.
139	H Guo, T Wang, H Wu, et al. Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model. Mol Autism. 2018;9:64.
140	Y Xie, Z Xu, M Xia, et al. Alterations in connectome dynamics in autism spectrum disorder: a harmonized mega- and meta-analysis study using the autism brain imaging data exchange dataset. Biol Psychiatry. 2022;91(11):945-955.
141	Y Sztainberg, HY Zoghbi. Lessons learned from studying syndromic autism spectrum disorders. Nat Neurosci. 2016;19(11):1408-1417.
142	L Shen, H Zhang, J Lin, et al. A combined proteomics and metabolomics profiling to investigate the genetic heterogeneity of autistic children. Mol Neurobiol. 2022;59(6):3529-3545.
143	J Ellegood, E Anagnostou, BA Babineau, et al. Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. Mol Psychiatry. 2015;20(1):118-125.
144	EA Brown, JD Lautz, TR Davis, et al. Clustering the autisms using glutamate synapse protein interaction networks from cortical and hippocampal tissue of seven mouse models. Mol Autism. 2018;9:48.
145	X Jin, SK Simmons, A Guo, et al. In vivo Perturb-Seq reveals neuronal and glial abnormalities associated with autism risk genes. Science. 2020;370(6520):eaaz6063.
146	AU Carbonell, C Freire-Cobo, IV Deyneko, et al. Comparing synaptic proteomes across five mouse models for autism reveals converging molecular similarities including deficits in oxidative phosphorylation and Rho GTPase signaling. Front Aging Neurosci. 2023;15:1152562.
147	V Zerbi, M Pagani, M Markicevic, et al. Brain mapping across 16 autism mouse models reveals a spectrum of functional connectivity subtypes. Mol Psychiatry. 2021;26(12):7610-7620.
148	HR Willsey, CRT Exner, Y Xu, et al. Parallel in vivo analysis of large-effect autism genes implicates cortical neurogenesis and estrogen in risk and resilience. Neuron. 2021;109(5):e8.
149	L Shen, H Zhang, J Lin, et al. A combined proteomics and metabolomics profiling to investigate the genetic heterogeneity of autistic children. Mol Neurobiol. 2022;59(6):3529-3545.
150	G Pintacuda, Y-HH Hsu, K Tsafou, et al. Protein interaction studies in human induced neurons indicate convergent biology underlying autism spectrum disorders. Cell Genomics. 2023;3(3):100250.
151	H Weinschutz Mendes, U Neelakantan, Y Liu, et al. High-throughput functional analysis of autism genes in zebrafish identifies convergence in dopaminergic and neuroimmune pathways. Cell Rep. 2023;42(3):112243.
152	HR Willsey, CRT Exner, Y Xu, et al. Parallel in vivo analysis of large-effect autism genes implicates cortical neurogenesis and estrogen in risk and resilience. Neuron. 2021;109(8):1409.
153	J Peng, Y Zhou, K Wang. Multiplex gene and phenotype network to characterize shared genetic pathways of epilepsy and autism. Sci Rep. 2021;11(1):952.
154	M Moyses-Oliveira, R Yadav, S Erdin, ME Talkowski. New gene discoveries highlight functional convergence in autism and related neurodevelopmental disorders. Curr Opin Genet Dev. 2020;65:195-206.
155	M Woodbury-Smith, DA Bilder, J Morgan, et al. Combined genome-wide linkage and targeted association analysis of head circumference in autism spectrum disorder families. J Neurodev Disord. 2017;9:5.
156	S De Rubeis, JD Buxbaum. Genetics and genomics of autism spectrum disorder: embracing complexity. Hum Mol Genet. 2015;24(R1):R24-R31.
157	Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179(7):1469-1482.e11.
158	J Grove, S Ripke, TD Als, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51(3):431-444.
159	D Yu, JH Sul, F Tsetsos, et al. Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry. 2019;176(3):217-227.
160	HR Willsey, AJ Willsey, B Wang, MW State. Genomics, convergent neuroscience and progress in understanding autism spectrum disorder. Nat Rev Neurosci. 2022;23(6):323-341.
161	L Choi, JY An. Genetic architecture of autism spectrum disorder: lessons from large-scale genomic studies. Neurosci Biobehav Rev. 2021;128:244-257.
162	C Bokobza, J Van Steenwinckel, S Mani, V Mezger, B Fleiss, P Gressens. Neuroinflammation in preterm babies and autism spectrum disorders. Pediatr Res. 2019;85(2):155-165.
163	MD Rudolph, AM Graham, E Feczko, et al. Maternal IL-6 during pregnancy can be estimated from newborn brain connectivity and predicts future working memory in offspring. Nat Neurosci. 2018;21(5):765-772.
164	VX Han, S Patel, HF Jones, et al. Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Transl Psychiatry. 2021;11(1):71.
165	C Bundgaard-Nielsen, MB Lauritsen, JK Knudsen, et al. Children and adolescents with attention deficit hyperactivity disorder and autism spectrum disorder share distinct microbiota compositions. Gut Microbes. 2023;15(1):2211923.
166	EA Mayer, D Padua, K Tillisch. Altered brain–gut axis in autism: comorbidity or causative mechanisms? Bioessays. 2014;36(10):933-939.
167	M Zhang, Y Chu, Q Meng, et al. A quasi-paired cohort strategy reveals the impaired detoxifying function of microbes in the gut of autistic children. Sci Adv. 2020;6(43):eaba3760.
168	DA Rossignol, RE Frye. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012;17(4):389-401.
169	M Gevezova, Y Sbirkov, V Sarafian, K Plaimas, A Suratanee, M Maes. Autistic spectrum disorder (ASD)—gene, molecular and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopment. Brain Behav Immun Health. 2023;30:100646.
170	I Pacheva, I Ivanov. Targeted biomedical treatment for autism spectrum disorders. Curr Pharm Des. 2019;25(41):4430-4453.
171	HK Hughes, RJ Moreno, P Ashwood. Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD). Brain Behav Immun. 2023;108:245-254.
172	A Meltzer, J Van de Water. The role of the immune system in autism spectrum disorder. Neuropsychopharmacology. 2017;42(1):284-298.
173	C Onore, M Careaga, P Ashwood. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2012;26(3):383-392.
174	X Liao, J Yang, H Wang, Y Li. Microglia mediated neuroinflammation in autism spectrum disorder. J Psychiatr Res. 2020;130:167-176.
175	S Majhi, S Kumar, LA Singh. Review on autism spectrum disorder: pathogenesis, biomarkers, pharmacological and non-pharmacological interventions. CNS Neurol Disord Drug Targets. 2023;22(5):659-677.
176	G Bj?rklund, NA Meguid, MA El-Bana, et al. Oxidative stress in autism spectrum disorder. Mol Neurobiol. 2020;57(5):2314-2332.
177	DA Rossignol, RE Frye. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290-314.
178	K Singh, IN Singh, E Diggins, et al. Developmental regression and mitochondrial function in children with autism. Ann Clin Transl Neurol. 2020;7(5):683-694.
179	C Giulivi, Y-F Zhang, A Omanska-Klusek, et al. Mitochondrial dysfunction in autism. JAMA. 2010;304(21):2389-2396.
180	P Srikantha, MH Mohajeri. The possible role of the microbiota–gut–brain-axis in autism spectrum disorder. Int J Mol Sci. 2019;20(9):2115.
181	M Gevezova, V Sarafian, G Anderson, M Maes. Inflammation and mitochondrial dysfunction in autism spectrum disorder. CNS Neurol Disord Drug Targets. 2020;19(5):320-333.
182	L Xiao, J Yan, T Yang, et al. Fecal microbiome transplantation from children with autism spectrum disorder modulates tryptophan and serotonergic synapse metabolism and induces altered behaviors in germ-free mice. Msystems. 2021;6(2):e01343-20.
183	G Sharon, NJ Cruz, D-W Kang, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell. 2019;177(6):1600-1618.
184	M Zhang, Y Chu, Q Meng, et al. A quasi-paired cohort strategy reveals the impaired detoxifying function of microbes in the gut of autistic children. Sci Adv. 2020;6(43):eaba3760.
185	HE Vuong, EY Hsiao. Emerging roles for the gut microbiome in autism spectrum disorder. Biol Psychiatry. 2017;81(5):411-423.
186	J Zhu, X Hua, T Yang, et al. Alterations in gut vitamin and amino acid metabolism are associated with symptoms and neurodevelopment in children with autism spectrum disorder. J Autism Dev Disord. 2022;52(7):3116-3128.
187	A Sarkar, SM Lehto, S Harty, TG Dinan, JF Cryan, PWJ Burnet. Psychobiotics and the manipulation of bacteria–gut–brain signals. Trends Neurosci. 2016;39(11):763-781.
188	EY Hsiao, SW McBride, S Hsien, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451-1463.
189	G Bj?rklund, L Pivina, M Dadar, et al. Gastrointestinal alterations in autism spectrum disorder: what do we know? Neurosci Biobehav Rev. 2020;118:111-120.
190	SA Buffington, SW Dooling, M Sgritta, et al. Dissecting the contribution of host genetics and the microbiome in complex behaviors. Cell. 2021;184(7):1740-1756.e16.
191	Y Yu, B Zhang, P Ji, et al. Changes to gut amino acid transporters and microbiome associated with increased E/I ratio in Chd8(+/–) mouse model of ASD-like behavior. Nat Commun. 2022;13(1):1151.
192	X Liu. The interaction of gut microbiota, genetic variation, and diet in autism spectrum disorder. mLife. 2022;1(3):241-244.
193	S Panelli, E Capelli, GFD Lupo, et al. Comparative study of salivary, duodenal, and fecal microbiota composition across adult celiac disease. J Clin Med. 2020;9(4):1109.
194	JW Bostick, AM Schonhoff, SK Mazmanian. Gut microbiome-mediated regulation of neuroinflammation. Curr Opin Immunol. 2022;76:102177.
195	F Liu, J Li, F Wu, H Zheng, Q Peng, H Zhou. Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review. Transl Psychiatry. 2019;9(1):43.
196	SL Hyman, SE Levy, SM Myers. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020;145(1):e20193447.
197	General Office of the National Health Commission. Notice of the General Office of the National Health Commission on exploring the Implementation of Special Services for the Prevention and Treatment of Depression and Senile Dementia.
198	S Cortese, K McGinn, M H?jlund, et al. The future of child and adolescent clinical psychopharmacology: a systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neurosci Biobehav Rev. 2023;149:105149.
199	M Parellada, á Andreu-Bernabeu, M Burdeus, et al. In search of biomarkers to guide interventions in autism spectrum disorder: a systematic review. Am J Psychiatry. 2023;180(1):23-40.
200	A Ansel, Y Posen, R Ellis, L Deutsch, PD Zisman, B Gesundheit. Biomarkers for autism spectrum disorders (ASD): a meta-analysis. Rambam Maimonides Med J. 2019;10(4):e0021.
201	MG Alharbi. Protein biomarkers in autistic children: a review. Asian J Biochem Genet Mol Biol. 2022;12(1):1-17.
202	C Feng, Y Chen, J Pan, et al. Redox proteomic identification of carbonylated proteins in autism plasma: insight into oxidative stress and its related biomarkers in autism. Clin Proteomics. 2017;14:2.
203	A Cortelazzo, C De Felice, R Guerranti, et al. Expression and oxidative modifications of plasma proteins in autism spectrum disorders: interplay between inflammatory response and lipid peroxidation. Proteomics Clin Appl. 2016;10(11):1103-1112.
204	L Shen, Y Zhao, H Zhang, et al. Advances in biomarker studies in autism spectrum disorders. Adv Exp Med Biol. 2019;1118:207-233.
205	J Abraham, N Szoko, MR Natowicz. Proteomic investigations of autism spectrum disorder: past findings, current challenges, and future prospects. Adv Exp Med Biol. 2019;1118:235-252.
206	N Likhitweerawong, C Thonusin, N Boonchooduang, et al. Profiles of urine and blood metabolomics in autism spectrum disorders. Metab Brain Dis. 2021;36(7):1641-1671.
207	XJ Xu, XE Cai, FC Meng, et al. Comparison of the metabolic profiles in the plasma and urine samples between autistic and typically developing boys: a preliminary study. Front Psychiatry. 2021;12:657105.
208	A Arora, F Mastropasqua, S B?lte, K Tammimies. Urine metabolomic profiles of autism and autistic traits—a twin study. medRxiv. 2023. 2023.04.24.23289030.
209	H Al-Otaish, L Al-Ayadhi, G Bj?rklund, S Chirumbolo, MA Urbina, A El-Ansary. Relationship between absolute and relative ratios of glutamate, glutamine and GABA and severity of autism spectrum disorder. Metab Brain Dis. 2018;33(3):843-854.
210	A El-Ansary, JJ Cannell, G Bj?rklund, et al. In the search for reliable biomarkers for the early diagnosis of autism spectrum disorder: the role of vitamin D. Metab Brain Dis. 2018;33(3):917-931.
211	H Zhang, X Tang, C Feng, et al. The use of data independent acquisition based proteomic analysis and machine learning to reveal potential biomarkers for autism spectrum disorder. J Proteomics. 2023;278:104872.
212	X Cao, X Tang, C Feng, et al. A systematic investigation of complement and coagulation-related protein in autism spectrum disorder using multiple reaction monitoring technology. Neurosci Bull. 2023;39(11):1623-1637.
213	S Dai, J Lin, Y Hou, X Luo, Y Shen, J Ou. Purine signaling pathway dysfunction in autism spectrum disorders: evidence from multiple omics data. Front Mol Neurosci. 2023;16:1089871.
214	W Liu, L Li, X Xia, et al. Integration of urine proteomic and metabolomic profiling reveals novel insights into neuroinflammation in autism spectrum disorder. Front Psychiatry. 2022;13:780747.
215	X Tang, C Feng, Y Zhao, et al. A study of genetic heterogeneity in autism spectrum disorders based on plasma proteomic and metabolomic analysis: multiomics study of autism heterogeneity. Med Comm (2020). 2023;4(5):e380.
216	NK Kordulewska, E Kostyra, K Piskorz-Ogórek, et al. Serum cytokine levels in children with spectrum autism disorder: differences in pro- and anti-inflammatory balance. J Neuroimmunol. 2019;337:577066.
217	CC Hu, X Xu, GL Xiong, et al. Alterations in plasma cytokine levels in Chinese children with autism spectrum disorder. Autism Res. 2018;11(7):989-999.
218	N Hoang, JA Buchanan, SW Scherer. Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders. NPJ Genom Med. 2018;3:27.
219	T Wang, H Guo, B Xiong, et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. Nat Commun. 2016;7:13316.
220	BA Corbett, AB Kantor, H Schulman, et al. A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry. 2007;12(3):292-306.
221	J Magdalon, F Mansur, ESAL Teles, VA de Goes, O Reiner, AL Sertié. Complement system in brain architecture and neurodevelopmental disorders. Front Neurosci. 2020;14:23.
222	M Druart, C Le Magueresse. Emerging roles of complement in psychiatric disorders. Front Psychiatry. 2019;10:573.
223	E Garcia-Gutierrez, A Narbad, JM Rodríguez. Autism spectrum disorder associated with gut microbiota at immune, metabolomic, and neuroactive level. Front Neurosci. 2020;14:578666.
224	PR West, DG Amaral, P Bais, et al. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS One. 2014;9(11):e112445.
225	A Anwar, PM Abruzzo, S Pasha, et al. Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism-a source of biomarkers for clinical diagnosis. Mol Autism. 2018;9(1):1-16.
226	J-B Delaye, F Patin, E Lagrue, et al. Post hoc analysis of plasma amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disability. Ann Clin Biochem. 2018;55(5):543-552.
227	Q-Q Lv, C You, X-B Zou, H-Z Deng. Acyl-carnitine, C5DC, and C26 as potential biomarkers for diagnosis of autism spectrum disorder in children. Psychiatry Res. 2018;267:277-280.
228	AM Smith, JJ King, PR West, et al. Amino acid dysregulation metabotypes: potential biomarkers for diagnosis and individualized treatment for subtypes of autism spectrum disorder. Biol Psychiatry. 2019;85(4):345-354.
229	D Brister, S Rose, L Delhey, et al. Metabolomic signatures of autism spectrum disorder. J Personalized Med. 2022;12(10):1727.
230	J Kaluzna-Czaplinska, E Socha, J Rynkowski. Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry. Med Sci Monit. 2010;16(9):CR445-CR450.
231	S Mavel, L Nadal-Desbarats, H Blasco, et al. 1H–13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta. 2013;114:95-102.
232	P Emond, S Mavel, N A?doud, et al. GC–MS-based urine metabolic profiling of autism spectrum disorders. Anal BioanalChem. 2013;405:5291-5300.
233	L Nadal-Desbarats, N A?doud, P Emond, et al. Combined 1H-NMR and 1H–13C HSQC-NMR to improve urinary screening in autism spectrum disorders. Analyst. 2014;139(13):3460-3468.
234	A Liu, W Zhou, L Qu, et al. Altered urinary amino acids in children with autism spectrum disorders. Front Cell Neurosci. 2019;13:7.
235	JB Delaye, F Patin, E Lagrue, et al. Post hoc analysis of plasma amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disability. Ann Clin Biochem. 2018;55(5):543-552.
236	AM Smith, JJ King, PR West, et al. Amino acid dysregulation metabotypes: potential biomarkers for diagnosis and individualized treatment for subtypes of autism spectrum disorder. Biol Psychiatry. 2019;85(4):345-354.
237	L Wang, CT Christophersen, MJ Sorich, JP Gerber, MT Angley, MA Conlon. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096-2102.
238	D Brister, S Rose, L Delhey, et al. Metabolomic signatures of autism spectrum disorder. J Pers Med. 2022;12(10):1727.
239	A Liu, W Zhou, L Qu, et al. Altered urinary amino acids in children with autism spectrum disorders. Front Cell Neurosci. 2019;13:7.
240	L Nadal-Desbarats, N Aidoud, P Emond, et al. Combined 1H-NMR and 1H-13C HSQC-NMR to improve urinary screening in autism spectrum disorders. Analyst. 2014;139(13):3460-3468.
241	D Olesova, J Galba, J Piestansky, et al. A novel UHPLC-MS method targeting urinary metabolomic markers for autism spectrum disorder. Metabolites. 2020;10(11):443.
242	J Mead, P Ashwood. Evidence supporting an altered immune response in ASD. Immunol Lett. 2015;163(1):49-55.
243	A Masi, DS Quintana, N Glozier, AR Lloyd, IB Hickie, AJ Guastella. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2015;20(4):440-446.
244	A Saghazadeh, B Ataeinia, K Keynejad, A Abdolalizadeh, A Hirbod-Mobarakeh, N Rezaei. A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: effects of age, gender, and latitude. J Psychiatr Res. 2019;115:90-102.
245	A Saghazadeh, B Ataeinia, K Keynejad, A Abdolalizadeh, A Hirbod-Mobarakeh, N Rezaei. Anti-inflammatory cytokines in autism spectrum disorders: a systematic review and meta-analysis. Cytokine. 2019;123:154740.
246	H Zhao, H Zhang, S Liu, W Luo, Y Jiang, J Gao. Association of peripheral blood levels of cytokines with autism spectrum disorder: a meta-analysis. Front Psychiatry. 2021;12:670200.
247	P Ashwood, P Krakowiak, I Hertz-Picciotto, R Hansen, IN Pessah, J Van de Water. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol. 2011;232(1-2):196-199.
248	P Ashwood, P Krakowiak, I Hertz-Picciotto, R Hansen, I Pessah, J Van de Water. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011;25(1):40-45.
249	V Napolioni, B Ober-Reynolds, S Szelinger, et al. Plasma cytokine profiling in sibling pairs discordant for autism spectrum disorder. J Neuroinflammation. 2013;10:38.
250	X Li, A Chauhan, AM Sheikh, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207(1–2):111-116.
251	DL Vargas, C Nascimbene, C Krishnan, AW Zimmerman, CA Pardo. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67-81.
252	MM Eftekharian, S Ghafouri-Fard, R Noroozi, et al. Cytokine profile in autistic patients. Cytokine. 2018;108:120-126.
253	L Chen, XJ Shi, H Liu, et al. Oxidative stress marker aberrations in children with autism spectrum disorder: a systematic review and meta-analysis of 87 studies (N=9109). Transl Psychiatry. 2021;11(1):15.
254	X Liu, J Lin, H Zhang, et al. Oxidative stress in autism spectrum disorder—current progress of mechanisms and biomarkers. Front Psychiatry. 2022;13:813304.
255	KA Bala, M Do?an, S Kaba, T Mutluer, O Aslan, SZ Do?an. Hormone disorder and vitamin deficiency in attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASDs). J Pediatr Endocrinol Metab. 2016;29(9):1077-1082.
256	M Fuentes-Albero, O Cauli. Homocysteine levels in autism spectrum disorder: a clinical update. Endocr Metab Immune Disord Drug Targets. 2018;18(4):289-296.
257	Y Zhang, NW Hodgson, MS Trivedi, et al. Decreased brain levels of vitamin B12 in aging, autism and schizophrenia. PLoS One. 2016;11(1):e0146797.
258	M Lou, A Cao, C Jin, et al. Deviated and early unsustainable stunted development of gut microbiota in children with autism spectrum disorder. Gut. 2022;71(8):1588-1599.
259	M De Angelis, M Piccolo, L Vannini, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013;8(10):e76993.
260	F Gevi, L Zolla, S Gabriele, AM Persico. Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism. Mol Autism. 2016;7:47.
261	Q Chen, Y Qiao, X-j Xu, X You, Y Tao. Urine organic acids as potential biomarkers for autism-spectrum disorder in Chinese children. Front Cellular Neurosci. 2019;13:150.
262	D-W Kang, JB Adams, T Vargason, M Santiago, J Hahn, R Krajmalnik-Brown. Distinct fecal and plasma metabolites in children with autism spectrum disorders and their modulation after microbiota transfer therapy. Msphere. 2020;5(5):e00314-e00320.
263	A Fattorusso, L Di Genova, GB Dell'Isola, E Mencaroni, S Esposito. Autism spectrum disorders and the gut microbiota. Nutrients. 2019;11(3):521.
264	A Mohamadkhani. Gut microbiota and fecal metabolome perturbation in children with autism spectrum disorder. Middle East J Dig Dis. 2018;10(4):205-212.
265	X Xu, X Zou, T Li. Expert consensus on early identification, screening and early intervention of children with autism spectrum disorders. Chin J Pediatr. 2017;55(12):890-897.
266	OD Howes, M Rogdaki, JL Findon, et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol. 2018;32(1):3-29.
267	M Sandbank, K Bottema-Beutel, S Crowley, et al. Project AIM: autism intervention meta-analysis for studies of young children. Psychol Bull. 2020;146(1):1.
268	SL Hyman, SE Levy, SM Myers, Council on Children With Disabilities, Section on Developmental and Behavioral Pediatrics. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020;145(1):e20193447.
269	CJ Gosling, A Cartigny, BC Mellier, A Solanes, J Radua, R Delorme. Efficacy of psychosocial interventions for Autism spectrum disorder: an umbrella review. Mol Psychiatry. 2022;27(9):3647-3656.
270	D Trembath, K Varcin, H Waddington, et al. Non-pharmacological interventions for autistic children: an umbrella review. Autism. 2023;27(2):275-295.
271	L French, EM Kennedy. Annual research review: early intervention for infants and young children with, or at-risk of, autism spectrum disorder: a systematic review. J Child Psychol Psychiatry. 2018;59(4):444-456.
272	RL Gabriels, Z Pan, B Dechant, JA Agnew, N Brim, G Mesibov. Randomized controlled trial of therapeutic horseback riding in children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(7):541-549.
273	K Bearss, C Johnson, T Smith, et al. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA. 2015;313(15):1524-1533.
274	? Bieleninik, M Geretsegger, K M?ssler, et al. Effects of improvisational music therapy vs enhanced standard care on symptom severity among children with autism spectrum disorder: the TIME—a randomized clinical trial. JAMA. 2017;318(6):525-535.
275	M Sharda, C Tuerk, R Chowdhury, et al. Music improves social communication and auditory–motor connectivity in children with autism. Transl Psychiatry. 2018;8(1):231.
276	R Grimaldi, GR Gibson, J Vulevic, et al. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 2018;6(1):133.
277	CL DeVane, JM Charles, RK Abramson, et al. Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacother J Human Pharmacol Drug Therapy. 2019;39(6):626-635.
278	C Voss, J Schwartz, J Daniels, et al. Effect of wearable digital intervention for improving socialization in children with autism spectrum disorder: a randomized clinical trial. JAMA Pediatr. 2019;173(5):446-454.
279	BA Malow, RL Findling, CM Schroder, et al. Sleep, growth, and puberty after 2 years of prolonged-release melatonin in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2021;60(2):252-261.e3.
280	JJ Wood, PC Kendall, KS Wood, et al. Cognitive behavioral treatments for anxiety in children with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2020;77(5):474-483.
281	L Sikich, A Kolevzon, BH King, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med. 2021;385(16):1462-1473.
282	A Aran, M Harel, H Cassuto, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021;12(1):6.
283	L Scahill, MA Shillingsburg, O Ousley, et al. A randomized trial of direct instruction language for learning in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2022;61(6):772-781.
284	L Chu, L Shen, C Ma, et al. Effects of a nonwearable digital therapeutic intervention on preschoolers with autism spectrum disorder in China: open-label randomized controlled trial. J Med Internet Res. 2023;25:e45836.
285	C Lord, T Charman, A Havdahl, et al. The Lancet Commission on the future of care and clinical research in autism. Lancet North Am Ed. 2022;399(10321):271-334.
286	L Kux. Food and Drug Administration [Docket No. FDA-2012-D-0146]: Guidance for Industry on Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment; Availability; Correction. Federal Register. Vol 77. Department of Health and Human Services. 2012:32124-32125.
287	G Dawson, R Bernier. A quarter century of progress on the early detection and treatment of autism spectrum disorder. Dev Psychopathol. 2013;25(4pt2): 1455-1472.
288	OI Lovaas. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol. 1987;55(1):3.
289	T Smith, S Iadarola. Evidence base update for autism spectrum disorder. J Clin Child Adolesc Psychol. 2015;44(6):897-922.
290	AR Cummings, JE Carr. Evaluating progress in behavioral programs for children with autism spectrum disorders via continuous and discontinuous measurement. J Appl Behav Anal. 2009;42(1):57-71.
291	DC Lerman, LH Dittlinger, G Fentress, T Lanagan. A comparison of methods for collecting data on performance during discrete trial teaching. Behav Anal Pract. 2011;4:53-62.
292	SM Myers, CP Johnson, American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics. 2007;120(5):1162-1182.
293	LA LeBlanc, AM Coates, S Daneshvar, MH Charlop-Christy, C Morris, BM Lancaster. Using video modeling and reinforcement to teach perspective-taking skills to children with autism. J Appl Behav Anal. 2003;36(2):253-257.
294	RL Koegel, MC O'dell, LK Koegel. A natural language teaching paradigm for nonverbal autistic children. J Autism Dev Disord. 1987;17(2):187-200.
295	AY Hardan, GW Gengoux, KL Berquist, et al. A randomized controlled trial of pivotal response treatment group for parents of children with autism. J Child Psychol Psychiatry. 2015;56(8):884-892.
296	F Mohammadzaheri, LK Koegel, M Rezaee, SM Rafiee. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) intervention for children with autism. J Autism Dev Disord. 2014;44:2769-2777.
297	C Batey, C Missiuna, B Timmons, J Hay, B Faught, J Cairney. Self-efficacy toward physical activity and the physical activity behavior of children with and without developmental coordination disorder. Hum Mov Sci. 2014;36:258-271.
298	BW Tan, JA Pooley, CP Speelman. A meta-analytic review of the efficacy of physical exercise interventions on cognition in individuals with autism spectrum disorder and ADHD. J Autism Dev Disord. 2016;46:3126-3143.
299	E Bremer, M Crozier, M Lloyd. A systematic review of the behavioural outcomes following exercise interventions for children and youth with autism spectrum disorder. Autism. 2016;20(8):899-915.
300	KN Oriel, CL George, R Peckus, A Semon. The effects of aerobic exercise on academic engagement in young children with autism spectrum disorder. Pediatric Phys Ther. 2011;23(2):187-193.
301	X Liang, R Li, SH Wong, et al. The effects of exercise interventions on executive functions in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Sports Med. 2022;52(1):75-88.
302	EJ Teh, R Vijayakumar, TXJ Tan, MJ Yap. Effects of physical exercise interventions on stereotyped motor behaviours in children with ASD: a meta-analysis. J Autism Dev Disord. 2022;52(7):2934-2957.
303	K-L Sam, B-C Chow, K-K Tong. Effectiveness of exercise-based interventions for children with autism: a systematic review and meta-analysis. Int J Learn Teach. 2015;1(2):98-103.
304	C Petrus, SR Adamson, L Block, SJ Einarson, M Sharifnejad, SR Harris. Effects of exercise interventions on stereotypic behaviours in children with autism spectrum disorder. Physiother Can. 2008;60(2):134-145.
305	CV Toscano, HM Carvalho, JP Ferreira. Exercise effects for children with autism spectrum disorder: metabolic health, autistic traits, and quality of life. Percept Mot Skills. 2018;125(1):126-146.
306	F Bahrami, A Movahedi, SM Marandi, C Sorensen. The effect of karate techniques training on communication deficit of children with autism spectrum disorders. J Autism Dev Disord. 2016;46:978-986.
307	RL Gabriels, JA Agnew, KD Holt, et al. Pilot study measuring the effects of therapeutic horseback riding on school-age children and adolescents with autism spectrum disorders. Autism Spectrum Disorders. 2012;6(2):578-588.
308	LJ Levinson, G Reid. The effects of exercise intensity on the stereotypic behaviors of individuals with autism. Adapt Phys Activity Quart. 1993;10(3):255-268.
309	A Rosenthal-Malek, S Mitchell. Brief report: the effects of exercise on the self-stimulatory behaviors and positive responding of adolescents with autism. J Autism Dev Disord. 1997;27(2):193-202.
310	C-Y Pan. Effects of water exercise swimming program on aquatic skills and social behaviors in children with autism spectrum disorders. Autism. 2010;14(1):9-28.
311	I Yilmaz, M Yanarda?, B Birkan, G Bumin. Effects of swimming training on physical fitness and water orientation in autism. Pediatr Int. 2004;46(5):624-626.
312	A Movahedi, F Bahrami, SM Marandi, A Abedi. Improvement in social dysfunction of children with autism spectrum disorder following long term Kata techniques training. Res Autism Spectrum Disorders. 2013;7(9):1054-1061.
313	T Todd, G Reid, L Butler-Kisber. Cycling for students with ASD: self-regulation promotes sustained physical activity. Adapt Phys Activity Quart. 2010;27(3):226-241.
314	KP Koenig, A Buckley-Reen, S Garg. Efficacy of the get ready to learn yoga program among children with autism spectrum disorders: a pretest–posttest control group design. Am J Occup Ther. 2012;66(5):538-546.
315	LE Rosenblatt, S Gorantla, JA Torres, et al. Relaxation response–based yoga improves functioning in young children with autism: a pilot study. J Alternative Complement Med. 2011;17(11):1029-1035.
316	CV Toscano, L Barros, AB Lima, T Nunes, HM Carvalho, JM Gaspar. Neuroinflammation in autism spectrum disorders: exercise as a “pharmacological” tool. Neurosci Biobehav Rev. 2021;129:63-74.
317	JP Ferreira, T Ghiarone, CRC Junior, et al. Effects of physical exercise on the stereotyped behavior of children with autism spectrum disorders. Medicina (Mex). 2019;55(10):685.
318	SS Olin, BA McFadden, DL Golem, et al. The effects of exercise dose on stereotypical behavior in children with autism. Med Sci Sports Exercise. 2017;49(5):983-990.
319	M Colasanto, S Madigan, DJ Korczak. Depression and inflammation among children and adolescents: a meta-analysis. J Affect Disord. 2020;277:940-948.
320	JJ Liu, YB Wei, R Strawbridge, et al. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry. 2020;25(2):339-350.
321	AE Reschke-Hernández. History of music therapy treatment interventions for children with autism. J Music Ther. 2011;48(2):169-207.
322	MD Brownell. Musically adapted social stories to modify behaviors in students with autism: four case studies. J Music Ther. 2002;39(2):117-144.
323	BS Fees, M Kaff, T Holmberg, J Teagarden, D Delreal. Children's responses to a social story song in three inclusive preschool classrooms: a pilot study. Music Ther Perspect. 2014;32(1):71-77.
324	P Kern, M Wolery, D Aldridge. Use of songs to promote independence in morning greeting routines for young children with autism. J Autism Dev Disord. 2007;37:1264-1271.
325	P Kern, D Aldridge. Using embedded music therapy interventions to support outdoor play of young children with autism in an inclusive community-based child care program. J Music Ther. 2006;43(4):270-294.
326	RS Kaplan, AL Steele. An analysis of music therapy program goals and outcomes for clients with diagnoses on the autism spectrum. J Music Ther. 2005;42(1):2-19.
327	J Kim, T Wigram, C Gold. The effects of improvisational music therapy on joint attention behaviors in autistic children: a randomized controlled study. J Autism Dev Disord. 2008;38:1758-1766.
328	AB LaGasse. Effects of a music therapy group intervention on enhancing social skills in children with autism. J Music Ther. 2014;51(3):250-275.
329	LO Ulfarsdottir, PG Erwin. The influence of music on social cognitive skills. Arts Psychother. 1999;26(2):81-84.
330	HA Lim. Effect of “developmental speech and language training through music” on speech production in children with autism spectrum disorders. J Music Ther. 2010;47(1):2-26.
331	HA Lim, E Draper. The effects of music therapy incorporated with applied behavior analysis verbal behavior approach for children with autism spectrum disorders. J Music Ther. 2011;48(4):532-550.
332	P Vaiouli, K Grimmet, LJ Ruich. “Bill is now singing”: joint engagement and the emergence of social communication of three young children with autism. Autism. 2015;19(1):73-83.
333	A Paul, M Sharda, S Menon, et al. The effect of sung speech on socio-communicative responsiveness in children with autism spectrum disorders. Front Human Neurosci. 2015;9:555.
334	BM Gee, K Thompson, H St John. Efficacy of a sound-based intervention with a child with an autism spectrum disorder and auditory sensory over-responsivity. Occup Ther Int. 2014;21(1):12-20.
335	A Hillier, G Greher, N Poto, M Dougherty. Positive outcomes following participation in a music intervention for adolescents and young adults on the autism spectrum. Psychol Music. 2012;40(2):201-215.
336	E Finnigan, E Starr. Increasing social responsiveness in a child with autism: a comparison of music and non-music interventions. Autism. 2010;14(4):321-348.
337	G Thompson, K McFerran, C Gold. Family-centred music therapy to promote social engagement in young children with severe autism spectrum disorder: a randomized controlled study. Child Care Health Dev. 2014;40(6):840-852.
338	ET Schwartzberg, MJ Silverman. Effects of music-based social stories on comprehension and generalization of social skills in children with autism spectrum disorders: a randomized effectiveness study. Arts Psychother. 2013;40(3):331-337.
339	BA Corbett, K Shickman, E Ferrer. Brief report: the effects of Tomatis sound therapy on language in children with autism. J Autism Dev Disord. 2008;38:562-566.
340	JT Rapp, TR Vollmer. Stereotype I: a review of behavioral assessment and treatment. Res Dev Disabil. 2005;26(6):527-547.
341	G Vivanti, HN Zhong. Naturalistic developmental behavioral interventions for children with autism. Clinical Guide to Early Interventions for Children With Autism. 2020:93-130.
342	TD Snyder, C De Brey, SA Dillow. Digest of Education Statistics 2014, NCES 2016-006. National Center for Education Statistics. 2016.
343	MA Murphy, LA Ruble. A comparative study of rurality and urbanicity on access to and satisfaction with services for children with autism spectrum disorders. Rural Special Educ Quart. 2012;31(3):3-11.
344	TL Burrell. Parents' involvement in ASD treatment: what is their role? Cognit Behav Pract. 2012;19(3):423-432.
345	JT Downer, RC Pianta. Academic and cognitive functioning in first grade: associations with earlier home and child care predictors and with concurrent home and classroom experiences. School Psychol Rev. 2006;35(1):11-30.
346	C Webster-Stratton, KC Herman. The impact of parent behavior-management training on child depressive symptoms. J Counsel Psychol. 2008;55(4):473.
347	AT Menting, BO de Castro, W Matthys. Effectiveness of the incredible years parent training to modify disruptive and prosocial child behavior: a meta-analytic review. Clin Psychol Rev. 2013;33(8):901-913.
348	C Neitzel, A Stright. Relations between mothers’ scaffolding and children's academic self-regulation: establishing a foundation of self-regulatory competence. J Fam Psychol. 2003;17(1):147-159.
349	KD Cline, CP Edwards. The instructional and emotional quality of parent–child book reading and early head start children's learning outcomes. Early Educ Dev. 2013;24(8):1214-1231.
350	B Ingersoll, A Wainer. Initial efficacy of Project ImPACT: a parent-mediated social communication intervention for young children with ASD. J Autism Dev Disord. 2013;43:2943-2952.
351	ML Matson, S Mahan, JL Matson. Parent training: a review of methods for children with autism spectrum disorders. Res Autism Spectrum Disorders. 2009;3(4):868-875.
352	H McConachie, T Diggle. Parent implemented early intervention for young children with autism spectrum disorder: a systematic review. J Eval Clin Pract. 2007;13(1):120-129.
353	C Wong, SL Odom, KA Hume, et al. Evidence-based practices for children, youth, and young adults with autism spectrum disorder: a comprehensive review. J Autism Dev Disord. 2015;45:1951-1966.
354	EM Kim, SM Sheridan. Foundational aspects of family–school connections: definitions, conceptual frameworks, and research needs. Foundational Aspects of Family–School Partnership Research. 2015:1-14.
355	SM Sheridan, JA Bovaird, TA Glover, S Andrew Garbacz, A Witte, K Kwon. A randomized trial examining the effects of conjoint behavioral consultation and the mediating role of the parent–teacher relationship. School Psychol Rev. 2012;41(1):23-46.
356	MJ Rispoli, JH Franco, L van der Meer, R Lang, SPH Camargo. The use of speech generating devices in communication interventions for individuals with developmental disabilities: a review of the literature. Dev Neurorehab. 2010;13(4):276-293.
357	P Mirenda. Toward functional augmentative and alternative communication for students with autism: manual signs, graphic symbols, and voice output communication aids. Lang Speech Hear Serv Sch. 2003;34(3):203-216.
358	ER Lorah, A Parnell, PS Whitby, D Hantula. A systematic review of tablet computers and portable media players as speech generating devices for individuals with autism spectrum disorder. J Autism Dev Disord. 2015;45:3792-3804.
359	ER Lorah, M Tincani, J Dodge, S Gilroy, A Hickey, D Hantula. Evaluating picture exchange and the iPad? as a speech generating device to teach communication to young children with autism. J Dev Phys Disab. 2013;25:637-649.
360	R Schlosser. Roles of speech output in augmentative and alternative communication: narrative review. Augment Altern Commun. 2003;19(1):5-27.
361	JB Ganz, TL Earles-Vollrath, AK Heath, RI Parker, MJ Rispoli, JB Duran. A meta-analysis of single case research studies on aided augmentative and alternative communication systems with individuals with autism spectrum disorders. J Autism Dev Disord. 2012;42:60-74.
362	RW Schlosser, RK Koul. Speech output technologies in interventions for individuals with autism spectrum disorders: a scoping review. Augment Altern Commun. 2015;31(4):285-309.
363	BA Mineo, W Ziegler, S Gill, D Salkin. Engagement with electronic screen media among students with autism spectrum disorders. J Autism Dev Disord. 2009;39:172-187.
364	M Schmidt, JM Laffey, CT Schmidt, X Wang, J Stichter. Developing methods for understanding social behavior in a 3D virtual learning environment. Comput Hum Behav. 2012;28(2):405-413.
365	J Bailenson, K Patel, A Nielsen, R Bajscy, S-H Jung, G Kurillo. The effect of interactivity on learning physical actions in virtual reality. Media Psychol. 2008;11(3):354-376.
366	J Blascovich, J Loomis, AC Beall, KR Swinth, CL Hoyt, JN Bailenson. Immersive virtual environment technology as a methodological tool for social psychology. Psychol Inquiry. 2002;13(2):103-124.
367	S Wallace, M Coleman, A Bailey. An investigation of basic facial expression recognition in autism spectrum disorders. Cogn Emotion. 2008;22(7):1353-1380.
368	MR Kandalaft, N Didehbani, DC Krawczyk, TT Allen, SB Chapman. Virtual reality social cognition training for young adults with high-functioning autism. J Autism Dev Disord. 2013;43:34-44.
369	P Pennisi, A Tonacci, G Tartarisco, et al. Autism and social robotics: a systematic review. Autism Res. 2016;9(2):165-183.
370	JJ Diehl, CR Crowell, M Villano, K Wier, K Tang, LD Riek. Clinical applications of robots in autism spectrum disorder diagnosis and treatment. Comprehensive Guide to Autism. 2014:411-422.
371	JJ Diehl, LM Schmitt, M Villano, CR Crowell. The clinical use of robots for individuals with autism spectrum disorders: a critical review. Res Autism Spectrum Disord. 2012;6(1):249-262.
372	DJ Ricks, MB Colton. Trends and Considerations in Robot-Assisted Autism Therapy. IEEE; 2010:4354-4359.
373	B Scassellati, H Admoni, M Matari?. Robots for use in autism research. Annu Rev Biomed Eng. 2012;14:275-294.
374	D Feil-Seifer, MJ Matari?. Toward Socially Assistive Robotics for Augmenting Interventions for Children With Autism Spectrum Disorders. Springer; 2009:201-210.
375	B Scassellati. How Social Robots Will Help Us to Diagnose, Treat, and Understand Autism. Springer; 2007:552-563.
376	J-J Cabibihan, H Javed, M Ang, SM Aljunied. Why robots? A survey on the roles and benefits of social robots in the therapy of children with autism. Int J Social Robot. 2013;5:593-618.
377	H Kumazaki, T Muramatsu, Y Yoshikawa, et al. Role-play-based guidance for job interviews using an android robot for individuals with autism spectrum disorders. Front Psychiatry. 2019;10:239.
378	SM Anzalone, E Tilmont, S Boucenna, et al. How children with autism spectrum disorder behave and explore the 4-dimensional (spatial 3D+ time) environment during a joint attention induction task with a robot. Res Autism Spectrum Disord. 2014;8(7):814-826.
379	B Robins, K Dautenhahn, RT Boekhorst, A Billard. Robotic assistants in therapy and education of children with autism: can a small humanoid robot help encourage social interaction skills? Universal Access Inform Soc. 2005;4:105-120.
380	H Kozima, C Nakagawa, N Kawai, D Kosugi, Y Yano. A Humanoid in Company With Children. IEEE; 2004:470-477.
381	H Kozima, C Nakagawa, Y Yasuda. Interactive Robots for Communication-Care: A Case-Study in Autism Therapy. IEEE; 2005:341-346.
382	J Maniram, SB Karrim, F Oosthuizen, E Wiafe. Pharmacological management of core symptoms and comorbidities of autism spectrum disorder in children and adolescents: a systematic review. Neuropsychiatr Disease Treat. 2022;18:1629-1644.
383	Y Yu, A Chaulagain, SA Pedersen, et al. Pharmacotherapy of restricted/repetitive behavior in autism spectrum disorder: a systematic review and meta-analysis. BMC Psychiatry. 2020;20(1):1-11.
384	JJ Lim, E Anagnostou. Biomedical interventions for autism spectrum disorder. Neurodevelopmental Pediatrics: Genetic and Environmental Influences. Springer; 2023:327-335.
385	S Deb, M Roy, B Limbu, M Bertelli. Anti-anxiety medications and novel treatments for autism. Handbook of Autism and Pervasive Developmental Disorder: Assessment, Diagnosis, and Treatment. Springer; 2022:1157-1172.
386	R Hurwitz, R Blackmore, P Hazell, K Williams, S Woolfenden. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database System Rev. 2012:CD008372.
387	S Mathew, S Bichenapally, V Khachatryan, et al. Role of serotoninergic antidepressants in the development of autism spectrum disorders: a systematic review. Cureus. 2022;14(8):e28505.
388	A H?ge, T Banaschewski, JK Buitelaar, et al. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD)—study protocol for a randomised controlled trial. Trials. 2016;17(1):1-16.
389	K Jobski, J H?fer, F Hoffmann, C Bachmann. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand. 2017;135(1):8-28.
390	R Rodrigues, MC Lai, A Beswick, et al. Practitioner review: pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. J Child Psychol Psychiatr. 2021;62(6):680-700.
391	CA Farmer, MG Aman. Aripiprazole for the treatment of irritability associated with autism. Expert Opin Pharmacother. 2011;12(4):635-640.
392	ST Hesapcioglu, MF Ceylan, M Kasak, CP Sen. Olanzapine, risperidone, and aripiprazole use in children and adolescents with autism spectrum disorders. Autism Spectrum Disorders. 2020;72:101520.
393	AM Reiersen, B Handen. Commentary on ‘Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)’. Evidence-Based Child Health Cochrane Rev J. 2011;6(4):1082-1085.
394	K Williams, DM Wheeler, N Silove, P Hazell. Cochrane review: selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Evidence-Based Child Health Cochrane Rev J. 2011;6(4):1044-1078.
395	DS Reddihough, C Marraffa, A Mouti, et al. Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA. 2019;322(16):1561-1569.
396	J Green, S Garg. Annual research review: the state of autism intervention science: progress, target psychological and biological mechanisms and future prospects. J Child Psychol Psychiatry. 2018;59(4):424-443.
397	K Murari, A Abushaibah, JM Rho, RW Turner, N Cheng. A clinically relevant selective ERK-pathway inhibitor reverses core deficits in a mouse model of autism. EBioMedicine. 2023;91:104565.
398	I Pacheva, I Ivanov. Targeted biomedical treatment for autism spectrum disorders. Curr Pharm Des. 2019;25(41):4430-4453.
399	S Majhi, S Kumar, L Singh. A review on autism spectrum disorder: pathogenesis, biomarkers, pharmacological and non-pharmacological interventions. CNS Neurol Disord Drug Targets. 2023;22(5):659-677.
400	Y Liu, Z Yang, Y Du, S Shi, Y Cheng. Antioxidant interventions in autism spectrum disorders: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110476.
401	S Bent, B Lawton, T Warren, et al. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Mol Autism. 2018;9:1-12.
402	F Hendouei, H Sanjari Moghaddam, MR Mohammadi, N Taslimi, F Rezaei, S Akhondzadeh. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial. J Clin Pharm Ther. 2020;45(2):324-334.
403	E Mousavinejad, MA Ghaffari, F Riahi, M Hajmohammadi, Z Tiznobeyk, M Mousavinejad. Coenzyme Q10 supplementation reduces oxidative stress and decreases antioxidant enzyme activity in children with autism spectrum disorders. Psychiatry Res. 2018;265:62-69.
404	M Nikoo, H Radnia, M Farokhnia, M-R Mohammadi, S Akhondzadeh. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015;38(1):11-17.
405	S Bent, RL Hendren, T Zandi, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry. 2014;53(6):658-666.
406	K Yui, M Koshiba, S Nakamura, Y Kobayashi. Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol. 2012;32(2):200-206.
407	RL Hendren, SJ James, F Widjaja, B Lawton, A Rosenblatt, S Bent. Randomized, placebo-controlled trial of methyl B12 for children with autism. J Child Adolesc Psychopharmacol. 2016;26(9):774-783.
408	R Lynch, EL Diggins, SL Connors, et al. Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study. Global Adv Health Med. 2017;6:2164957×17735826.
409	LY Al-Ayadhi, NE Elamin. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evid-Based Complement Altern Med. 2013;2013:602834.
410	MB Sporn, KT Liby. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12(8):564-571.
411	J Yang, X Fu, X Liao, Y Li. Nrf2 activators as dietary phytochemicals against oxidative stress, inflammation, and mitochondrial dysfunction in autism spectrum disorders: a systematic review. Front Psychiatr. 2020;11:561998.
412	X Liu, J Lin, H Zhang, et al. Oxidative stress in autism spectrum disorder—current progress of mechanisms and biomarkers. Front Psychiatry. 2022;13:813304.
413	RE Frye, J Sequeira, E Quadros, S James, D Rossignol. Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol Psychiatry. 2013;18(3):369-381.
414	SJ James, S Melnyk, G Fuchs, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr. 2009;89(1):425-430.
415	RE Frye, S Melnyk, G Fuchs, et al. Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat. 2013;2013:609705.
416	RK Naviaux, B Curtis, K Li, et al. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. Ann Clin Transl Neurol. 2017;4(7):491-505.
417	L Pangrazzi, L Balasco, Y Bozzi. Natural antioxidants: a novel therapeutic approach to autism spectrum disorders? Antioxidants. 2020;9(12):1186.
418	MM Al-Amin, MM Rahman, FR Khan, F Zaman, HM Reza. Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism. Behav Brain Res. 2015;286:112-121.
419	M Ajami, H Pazoki-Toroudi, H Amani, et al. Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols. Neurosci Biobehav Rev. 2017;73:39-47.
420	B Bertolino, R Crupi, D Impellizzeri, et al. Beneficial effects of co-ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism. CNS Neurosci Ther. 2017;23(1):87-98.
421	P Bozzatello, E Brignolo, E De Grandi, S Bellino. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5(8):67.
422	H Niederhofer. First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder. Phytother Res. 2009;23(11):1645-1646.
423	R Singh, A Kisku, H Kungumaraj, et al. Autism spectrum disorders: a recent update on targeting inflammatory pathways with natural anti-inflammatory agents. Biomedicines. 2023;11(1):115.
424	X Liao, Y Li. Nuclear factor kappa B in autism spectrum disorder: a systematic review. Pharmacol Res. 2020;159:104918.
425	P Xin, X Xu, C Deng, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
426	E Parker-Athill, D Luo, A Bailey, et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol. 2009;217(1–2):20-27.
427	A Zawadzka, M Cie?lik, A Adamczyk. The role of maternal immune activation in the pathogenesis of autism: a review of the evidence, proposed mechanisms and implications for treatment. Int J Mol Sci. 2021;22(21):11516.
428	GB Choi, YS Yim, H Wong, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351(6276):933-939.
429	J Marchezan, EGA Winkler dos Santos, I Deckmann, R Dos Santos Riesgo. Immunological dysfunction in autism spectrum disorder: a potential target for therapy. NeuroImmunoModulation. 2019;25(5–6):300-319.
430	G Arteaga-Henríquez, L Gisbert, JA Ramos-Quiroga. Immunoregulatory and/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: a narrative review of randomized, placebo-controlled trials. CNS Drugs. 2023;37(3):215-229.
431	S Siafis, O ??ray, H Wu, et al. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism. 2022;13(1):1-17.
432	S Hafizi, D Tabatabaei, M-C Lai. Review of clinical studies targeting inflammatory pathways for individuals with autism. Front Psychiatr. 2019;10:849.
433	J Liu, Z Gao, C Liu, et al. Alteration of gut microbiota: new strategy for treating autism spectrum disorder. Front Cell Dev Biol. 2022;10:792490.
434	AV Rao, AC Bested, TM Beaulne, et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens. 2009;1(1):1-6.
435	D Silk, A Davis, J Vulevic, G Tzortzis, G Gibson. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(5):508-518.
436	G Liu, L Yuan. Analysis on the etiology, pathogenesis and syndrome differentiation of children with autism in traditional Chinese medicine. Liaoning J Trad Chin Med. 2007;9:1226-1227.
437	X Jiang, Z Cai, Z Zhang, A Li, Y Cheng, Y Lyu. Combined treatment of children with autism with modified yinhuo decoction and therapeutic interventions. Chin J Trad Chin Med Pharm. 2016;31(10):4322-4324.
438	N Zhou, Y Li, X Jiang, Y Lu. Clinical observation of supplemented Lizhong decoction in treating children autism. J New Chin Med. 2015;47(6):200-202.
439	H Wu, Z Wu. Trinity‘’ traditional chinese medicine treatment of autism. Chin Med Herald. 2006;11:116-117.
440	D-W Kang, JB Adams, AC Gregory, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):1-16.
441	S Zhang, Q Chen, CR Kelly, et al. Donor screening for fecal microbiota transplantation in China: evaluation of 8483 candidates. Gastroenterology. 2022;162(3):966-968.e3.
442	J Wang, Y Cao, W Hou, et al. Fecal microbiota transplantation improves VPA-induced ASD mice by modulating the serotonergic and glutamatergic synapse signaling pathways. Transl Psychiatry. 2023;13(1):17.
443	D-W Kang, JB Adams, DM Coleman, et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821.
444	V Saurman, KG Margolis, RA Luna. Autism spectrum disorder as a brain–gut–microbiome axis disorder. Dig Dis Sci. 2020;65(3):818-828.